TACSTD2 and triple-negative breast carcinoma: In further exploration, an anti-trophoblast cell surface antigen 2 (Trop2) ADC named sacituzumab govitecan (IMMU-132, Trodelvy, SG) was also approved for treating triple-negative breast cancers (TNBCs) [11].